Ecopipam
Sponsors
Psyadon Pharma, Emalex Biosciences Inc., William Ondo, MD
Conditions
AugmentationChildhood-Onset Fluency Disorder (Stuttering)Drug InteractionLesch-Nyhan DiseasePathological GamblingRestless Legs SyndromeSelf-injurious BehaviorTourette Syndrome
Phase 1
Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease
CompletedNCT01065558
Start: 2010-02-28End: 2011-06-30Updated: 2013-04-18
Ecopipam Treatment of Tourette Syndrome
CompletedNCT01244633
Start: 2010-10-31End: 2013-07-31Updated: 2015-09-29
Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist
CompletedNCT03218969
Start: 2017-09-18End: 2018-11-28Updated: 2026-04-27
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport
CompletedNCT05334108
Start: 2022-04-26End: 2022-08-26Updated: 2022-12-12
Drug Interaction Study
CompletedNCT06194864
Start: 2024-01-18End: 2024-05-22Updated: 2024-09-19
Phase 2
Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
CompletedNCT01215357
Start: 2010-10-31End: 2012-08-31Updated: 2024-05-14
Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years
CompletedNCT02102698
Start: 2014-06-19End: 2019-12-01Updated: 2026-05-22
Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents
CompletedNCT04007991
Start: 2019-06-28End: 2021-09-23Updated: 2023-10-04
Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension
CompletedNCT04114539
Start: 2019-10-04End: 2022-11-11Updated: 2024-02-01
Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)
CompletedNCT04492956
Start: 2020-10-02End: 2022-04-04Updated: 2022-04-28
Phase 3
Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease
TerminatedNCT01751802
Start: 2012-12-31End: 2014-12-31Updated: 2024-04-22
A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
Active, not recruitingNCT06021522
Start: 2023-08-16End: 2028-02-01Target: 150Updated: 2026-07-22